可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:
[1] Effect of etoprolol CR/XL in chronic heart disease: Metoprolol CR/XL Randimized Intervention Trial in Congestive Heart Failure(MERITHF)[J]. Lancet, 1999, 353(9169):2001-2007.
[2] The Cardiac Insufficiency Bisoprolol studyⅡ(CIBISⅡ): a randimized trial[J]. Lancet, 1999, 353(9146):9-13.
[3] Wilkins BJ, Dai YS, Bueno OF, et al. Calcineruin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy[J]. Cir Res, 2004, 94(1):110-118.
[4] Li X, Yang Y, Hu Y, et al. δVβ6Fyn signaling promotes oral cancer progression[J]. J Biol Chem, 2003, 278(43):41646-41653.
[5] Cheng HJ, Zhang ZS, Cheng CP, et al. Upregulation of function β3adrenergic receptors in the failing canine myocardium[J]. Cir Res, 2001, 89(7):599-606.
[6] Skeberdis VA. Structure and function of beta3adrenergic receptors[J]. Medicine, 2004, 40(5):407-413.
[7] 张鑫,杨永健. 缬沙坦对压力负荷心肌肥厚钙调神经磷酸酶(CaN)通路的作用[J]. 高血压杂志, 2005, 13(6):358-362.
[8] Petrich BG, Eloff BC, Lerner DL, et al. Targeted activation of cJun Nterminal kinase in vivo induces restrictive cardiomyopathy and conduction defects[J]. J Biol Chem, 2004, 279(15):15330-15338.
[9] Dzimiri N, AlBahnasi K, AlHalees Z. Myocardial hypertrophy is not a prerequisite for changes in early gene expression in left ventricular volume overload[J]. Fundam Clin Pharmacol, 2004, 18(1):39-44.